-+ 0.00%
-+ 0.00%
-+ 0.00%
Zealand Pharma starts Phase 2 trial of petrelintide-enicepatide combination for obesity
Share
Listen to the news
Zealand Pharma starts Phase 2 trial of petrelintide-enicepatide combination for obesity
  • Zealand Pharma initiated the Phase 2 ZYNERGY trial of petrelintide with enicepatide in people with obesity or overweight with weight-related comorbidities.
  • The study tests three once-weekly combination dosing regimens over 40 weeks against placebo or either drug alone.
  • The trial will assess weight loss, safety and tolerability; results are pending.
  • The combination aims to improve weight loss and cardiometabolic risk markers while maintaining tolerability, supporting an amylin-based weight-management franchise.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zealand Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611180100PRIMZONEFULLFEED1001304194) on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending